These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Chouhan JD; Herrington JD Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632 [TBL] [Abstract][Full Text] [Related]
4. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874 [TBL] [Abstract][Full Text] [Related]
5. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274 [TBL] [Abstract][Full Text] [Related]
6. Romiplostim: a review of its use in immune thrombocytopenia. Keating GM Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355 [TBL] [Abstract][Full Text] [Related]
7. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824 [TBL] [Abstract][Full Text] [Related]
8. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127 [TBL] [Abstract][Full Text] [Related]
9. Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim. Raval JS; Redner RL; Kiss JE J Clin Apher; 2013 Aug; 28(4):321-4. PubMed ID: 23450778 [TBL] [Abstract][Full Text] [Related]
10. Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia. Mokhtar GM; Tantawy AA; El Sherif NH Platelets; 2012; 23(4):264-73. PubMed ID: 22471399 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Cines DB; Wasser J; Rodeghiero F; Chong BH; Steurer M; Provan D; Lyons R; Garcia-Chavez J; Carpenter N; Wang X; Eisen M Haematologica; 2017 Aug; 102(8):1342-1351. PubMed ID: 28411254 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Kuter DJ; Bussel JB; Lyons RM; Pullarkat V; Gernsheimer TB; Senecal FM; Aledort LM; George JN; Kessler CM; Sanz MA; Liebman HA; Slovick FT; de Wolf JT; Bourgeois E; Guthrie TH; Newland A; Wasser JS; Hamburg SI; Grande C; Lefrère F; Lichtin AE; Tarantino MD; Terebelo HR; Viallard JF; Cuevas FJ; Go RS; Henry DH; Redner RL; Rice L; Schipperus MR; Guo DM; Nichol JL Lancet; 2008 Feb; 371(9610):395-403. PubMed ID: 18242413 [TBL] [Abstract][Full Text] [Related]
13. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider. Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799 [TBL] [Abstract][Full Text] [Related]
14. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685 [TBL] [Abstract][Full Text] [Related]
15. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Iwato K; Okamoto S; Kurokawa M; Kirito K; Hashino S; Ninomiya H; Mori S; Yonemura Y; Usuki K; Wei H; Lizambri R Int J Hematol; 2012 Jun; 95(6):652-9. PubMed ID: 22532046 [TBL] [Abstract][Full Text] [Related]
16. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura. Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585 [TBL] [Abstract][Full Text] [Related]
17. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim. Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524 [TBL] [Abstract][Full Text] [Related]
18. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim. Al-Samkari H; Van Cott EM; Kuter DJ Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804 [TBL] [Abstract][Full Text] [Related]
19. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Elalfy MS; Abdelmaksoud AA; Eltonbary KY Ann Hematol; 2011 Nov; 90(11):1341-4. PubMed ID: 21318572 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of Immune Thrombocytopenic Purpura (ITP) with the thrombopoietin-mimetic romiplostim. Meletis J; Katsandris A; Raptis SD; Mantzourani M Med Sci Monit; 2010 Aug; 16(8):CS100-2. PubMed ID: 20671616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]